| Dr John E Thompson, MD | |
|
22792 Harrisburg Westville Rd, Alliance, OH 44601-9224 | |
| (330) 823-4000 | |
| (330) 829-2919 |
| Full Name | Dr John E Thompson |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 35 Years |
| Location | 22792 Harrisburg Westville Rd, Alliance, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134122351 | NPI | - | NPPES |
| 0887358 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 35063843T (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Salem Regional Medical Center | Salem, OH | Hospital |
| University Hospitals Portage Medical Center | Ravenna, OH | Hospital |
| University Hospitals Of Cleveland | Cleveland, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sch Professional Corporation | 0941291868 | 54 |
| University Hospitals Medical Group Inc | 4789682493 | 1466 |
News Archive
Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has expanded its plans for its United States Food and Drug Administration (FDA) Expanded Access Treatment IND Program for its flagship product, Generex Oral-lyn™, to include licensed and qualified Nurse Practitioners in the United States.
Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms.
Scientists at Karolinska Institutet in Sweden and University of North Carolina, USA, have identified the cell types underlying schizophrenia in a new study published in Nature Genetics. The findings offer a roadmap for the development of new therapies to target the condition.
Which antiplatelet medication is best after a coronary stent? The Tailored Antiplatelet Therapy to Lessen Outcomes After Percutaneous Coronary Intervention (TAILOR-PCI) Study examines whether prescribing heart medication based on a patient's CYP2C19 genotype will help prevent heart attack, stroke, unstable angina, and cardiovascular death in patients who undergo percutaneous coronary intervention (PCI), commonly called angioplasty.
› Verified 1 days ago
| Entity Name | Inpatient Medical Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093756314 PECOS PAC ID: 6406753045 Enrollment ID: O20031212000790 |
News Archive
Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has expanded its plans for its United States Food and Drug Administration (FDA) Expanded Access Treatment IND Program for its flagship product, Generex Oral-lyn™, to include licensed and qualified Nurse Practitioners in the United States.
Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms.
Scientists at Karolinska Institutet in Sweden and University of North Carolina, USA, have identified the cell types underlying schizophrenia in a new study published in Nature Genetics. The findings offer a roadmap for the development of new therapies to target the condition.
Which antiplatelet medication is best after a coronary stent? The Tailored Antiplatelet Therapy to Lessen Outcomes After Percutaneous Coronary Intervention (TAILOR-PCI) Study examines whether prescribing heart medication based on a patient's CYP2C19 genotype will help prevent heart attack, stroke, unstable angina, and cardiovascular death in patients who undergo percutaneous coronary intervention (PCI), commonly called angioplasty.
› Verified 1 days ago
| Entity Name | Sch Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619959822 PECOS PAC ID: 0941291868 Enrollment ID: O20040520000126 |
News Archive
Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has expanded its plans for its United States Food and Drug Administration (FDA) Expanded Access Treatment IND Program for its flagship product, Generex Oral-lyn™, to include licensed and qualified Nurse Practitioners in the United States.
Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms.
Scientists at Karolinska Institutet in Sweden and University of North Carolina, USA, have identified the cell types underlying schizophrenia in a new study published in Nature Genetics. The findings offer a roadmap for the development of new therapies to target the condition.
Which antiplatelet medication is best after a coronary stent? The Tailored Antiplatelet Therapy to Lessen Outcomes After Percutaneous Coronary Intervention (TAILOR-PCI) Study examines whether prescribing heart medication based on a patient's CYP2C19 genotype will help prevent heart attack, stroke, unstable angina, and cardiovascular death in patients who undergo percutaneous coronary intervention (PCI), commonly called angioplasty.
› Verified 1 days ago
| Entity Name | University Hospitals Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669499414 PECOS PAC ID: 4789682493 Enrollment ID: O20061113000301 |
News Archive
Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has expanded its plans for its United States Food and Drug Administration (FDA) Expanded Access Treatment IND Program for its flagship product, Generex Oral-lyn™, to include licensed and qualified Nurse Practitioners in the United States.
Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms.
Scientists at Karolinska Institutet in Sweden and University of North Carolina, USA, have identified the cell types underlying schizophrenia in a new study published in Nature Genetics. The findings offer a roadmap for the development of new therapies to target the condition.
Which antiplatelet medication is best after a coronary stent? The Tailored Antiplatelet Therapy to Lessen Outcomes After Percutaneous Coronary Intervention (TAILOR-PCI) Study examines whether prescribing heart medication based on a patient's CYP2C19 genotype will help prevent heart attack, stroke, unstable angina, and cardiovascular death in patients who undergo percutaneous coronary intervention (PCI), commonly called angioplasty.
› Verified 1 days ago
| Entity Name | 4m Hospitalist Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508288531 PECOS PAC ID: 0446480966 Enrollment ID: O20140303000908 |
News Archive
Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has expanded its plans for its United States Food and Drug Administration (FDA) Expanded Access Treatment IND Program for its flagship product, Generex Oral-lyn™, to include licensed and qualified Nurse Practitioners in the United States.
Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms.
Scientists at Karolinska Institutet in Sweden and University of North Carolina, USA, have identified the cell types underlying schizophrenia in a new study published in Nature Genetics. The findings offer a roadmap for the development of new therapies to target the condition.
Which antiplatelet medication is best after a coronary stent? The Tailored Antiplatelet Therapy to Lessen Outcomes After Percutaneous Coronary Intervention (TAILOR-PCI) Study examines whether prescribing heart medication based on a patient's CYP2C19 genotype will help prevent heart attack, stroke, unstable angina, and cardiovascular death in patients who undergo percutaneous coronary intervention (PCI), commonly called angioplasty.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John E Thompson, MD 22792 Harrisburg Westville Rd, Alliance, OH 44601-9224 Ph: (330) 823-4000 | Dr John E Thompson, MD 22792 Harrisburg Westville Rd, Alliance, OH 44601-9224 Ph: (330) 823-4000 |
News Archive
Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has expanded its plans for its United States Food and Drug Administration (FDA) Expanded Access Treatment IND Program for its flagship product, Generex Oral-lyn™, to include licensed and qualified Nurse Practitioners in the United States.
Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms.
Scientists at Karolinska Institutet in Sweden and University of North Carolina, USA, have identified the cell types underlying schizophrenia in a new study published in Nature Genetics. The findings offer a roadmap for the development of new therapies to target the condition.
Which antiplatelet medication is best after a coronary stent? The Tailored Antiplatelet Therapy to Lessen Outcomes After Percutaneous Coronary Intervention (TAILOR-PCI) Study examines whether prescribing heart medication based on a patient's CYP2C19 genotype will help prevent heart attack, stroke, unstable angina, and cardiovascular death in patients who undergo percutaneous coronary intervention (PCI), commonly called angioplasty.
› Verified 1 days ago
Puran Karra, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 E State St, Alliance, OH 44601 Phone: 330-596-6100 | |
Dr. Fidelis Okechukwu Mkparu, MD Internal Medicine Medicare: May Accept Medicare Assignments Practice Location: 2565 S Union Ave, Alliance, OH 44601 Phone: 330-823-0894 Fax: 330-823-4871 | |
Mark E Hostettler, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1207 W State St, Suite N, Alliance, OH 44601 Phone: 330-821-3244 Fax: 330-868-5782 | |
Dr. Michelle L Ahmed, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 22792 Harrisburg Westville Rd, Alliance, OH 44601 Phone: 330-823-4000 Fax: 330-829-2919 | |
Zev Randy Maycon, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 270 E State St, Suite G110, Alliance, OH 44601 Phone: 330-829-0951 Fax: 330-596-8696 | |
Dr. Ferdinando Cortese, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 885 S Sawburg Rd, Ste 110, Alliance, OH 44601 Phone: 330-829-4234 Fax: 330-829-4209 |